Positron-Emitting Radiopharmaceuticals
Provide an overview of radionuclides with relevant applications in PET.
- PDF / 2,701,161 Bytes
- 42 Pages / 595.276 x 790.866 pts Page_size
- 27 Downloads / 179 Views
Positron-Emitting Radiopharmaceuticals Piero A. Salvadori, Elena Filidei, and Assuero Giorgetti
Contents 3.1 Section I: Positron-Emitting Radionuclides and Labeling Strategies 3.1.1 Positron-Emitting Radionuclides and Basic Chemistry 3.1.2 Substrate Characteristics and Radiolabeling Strategies 3.1.3 Radiopharmaceuticals and Biological Systems 3.1.4 Production Flowchart and Related Issues 3.1.5 Basic of Automation and Synthesis Devices 3.1.6 18F-Labeled Radiopharmaceuticals 3.1.7 11C-Labeled Radiopharmaceuticals 3.1.8 68Ga-Labeled and Radiometal-Based Radiopharmaceuticals 3.1.9 Miscellanea 3.1.10 What Might Be Next
58 58 60 61 66 67 69 73 75 78 79
3.2 Section II: Positron-Emitting Radiopharmaceuticals for Clinical Use 3.2.1 Sodium 18F-Fluoride 3.2.2 Flow/Perfusion Agents 3.2.3 Energy Substrates 3.2.4 Substrates for Phospholipid Synthesis 3.2.5 Substrates for Protein Synthesis 3.2.6 Substrates for DNA Synthesis 3.2.7 Positron-Emitting Agents Based on Ligand-Acceptor Interaction 3.2.8 Amyloid Imaging Agents 3.2.9 Tissue Hypoxia Imaging Agents 3.2.10 Neoangiogenesis Imaging Agents 3.2.11 Apoptosis Imaging Agents
79 79 80 81 85 86 89 90 92 93 94 95
Further Reading
96
Learning Objectives
• Provide an overview of radionuclides with relevant applications in PET. • Define structure-activity relationships and how radiolabeling can induce molecular/biological perturbation. • Describe routes of administration and their impact on biodistribution. P. A. Salvadori (*) PET/Cyclotron Unit, CNR Institute of Clinical Physiology, Pisa, Italy e-mail: [email protected] E. Filidei · A. Giorgetti Nuclear Medicine Unit, Fondazione CNR/Regione Toscana Gabriele Monasterio, Pisa, Italy
• Describe the impact of molecular size, polarity, and functional groups on distribution. • Summarize key issues on handling positron-emitting radionuclides (shielding) and radiochemical synthesis. • Explain main advantages and issues regarding 11C-labeled radiopharmaceuticals. • Provide basic information on 68Ga-labeled radiopharmaceuticals and the 68Ge/68Ga generator. • Provide basic information on the synthesis and use of 124 I-labeled radiopharmaceuticals. • Provide information on the rationale for using positronemitting radiopharmaceuticals in different pathophysiologic conditions according to the biologic/metabolic event targeted by different classes of imaging agents.
© Springer Nature Switzerland AG 2019 D. Volterrani et al. (eds.), Nuclear Medicine Textbook, https://doi.org/10.1007/978-3-319-95564-3_3
57
58
3.1
P. A. Salvadori et al.
ection I: Positron-Emitting S Radionuclides and Labeling Strategies
Imaging with positron emission tomography (PET) is based on the detection of the annihilation radiation. Annihilation radiation occurs when matter is converted to energy. This phenomenon occurs when a negatively charged electron (negatron) and a positively charged electron (positron, emitted in the course of decay o
Data Loading...
